Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
28 07 2022
Historique:
pubmed: 15 7 2022
medline: 30 7 2022
entrez: 14 7 2022
Statut: ppublish

Résumé

SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS

Identifiants

pubmed: 35833726
doi: 10.1021/acs.jmedchem.2c00741
pmc: PMC9340770
doi:

Substances chimiques

Acetonitriles 0
KRAS protein, human 0
Piperazines 0
Pyrimidines 0
SOS1 Protein 0
adagrasib 8EOO6HQF8Y
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

9678-9690

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM124165
Pays : United States
Organisme : NIH HHS
ID : S10 OD021527
Pays : United States

Références

J Biol Chem. 2007 Jul 13;282(28):20245-55
pubmed: 17510059
J Med Chem. 2021 May 27;64(10):6569-6580
pubmed: 33719426
Cancer Surv. 1996;27:87-100
pubmed: 8909796
Science. 1997 Jul 18;277(5324):333-8
pubmed: 9219684
Genes Cancer. 2011 Mar;2(3):298-305
pubmed: 21779500
Br J Cancer. 2000 Mar;82(5):1035-40
pubmed: 10737386
Curr Opin Chem Biol. 2021 Jun;62:109-118
pubmed: 33848766
Cell. 2003 Mar 7;112(5):685-95
pubmed: 12628188
J Med Chem. 2018 Oct 11;61(19):8875-8894
pubmed: 30205005
Nat Genet. 2007 Jan;39(1):70-4
pubmed: 17143285
Cancer Res. 1989 Sep 1;49(17):4682-9
pubmed: 2547513
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188445
pubmed: 33035641
J Med Chem. 2015 Mar 12;58(5):2265-74
pubmed: 25695162
J Med Chem. 2022 Mar 10;65(5):3923-3942
pubmed: 35230841
J Med Chem. 2020 Jul 9;63(13):6679-6693
pubmed: 32250617
ACS Chem Biol. 2019 Mar 15;14(3):325-331
pubmed: 30735352
J Med Chem. 2019 Dec 26;62(24):10955-10994
pubmed: 31385704
Mol Cancer Ther. 2018 May;17(5):1051-1060
pubmed: 29440291
Curr Drug Metab. 2008 Jan;9(1):46-59
pubmed: 18220571
Nat Genet. 2007 Jan;39(1):75-9
pubmed: 17143282
N Engl J Med. 2021 Jun 24;384(25):2371-2381
pubmed: 34096690
J Clin Oncol. 2022 Feb 15;:JCO2102752
pubmed: 35167329
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3401-6
pubmed: 24550516
J Med Chem. 2018 Jul 26;61(14):6002-6017
pubmed: 29856609
J Med Chem. 2021 May 27;64(10):6566-6568
pubmed: 33961431
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2551-2560
pubmed: 30683722
Cancer. 2019 Dec 15;125(24):4380-4387
pubmed: 31469421
J Med Chem. 2020 Jan 9;63(1):52-65
pubmed: 31820981
Oncogene. 1995 Oct 5;11(7):1417-26
pubmed: 7478566
Bioorg Chem. 2020 Jun;99:103811
pubmed: 32278207
Cell. 2017 Jun 29;170(1):17-33
pubmed: 28666118
J Med Chem. 2020 Aug 13;63(15):8325-8337
pubmed: 32673492
Anal Biochem. 2018 May 1;548:44-52
pubmed: 29444450
Am J Hum Genet. 2002 Apr;70(4):943-54
pubmed: 11868160
Cancer Discov. 2021 Jan;11(1):142-157
pubmed: 32816843
Nat Commun. 2012;3:1168
pubmed: 23132018
ACS Med Chem Lett. 2018 Aug 08;9(9):941-946
pubmed: 30258545
Mol Cell Biol. 1996 Oct;16(10):5674-82
pubmed: 8816480
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Nature. 1998 Jul 23;394(6691):337-43
pubmed: 9690470
Exp Cell Res. 2021 Mar 1;400(1):112508
pubmed: 33549576

Auteurs

John M Ketcham (JM)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Jacob Haling (J)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Shilpi Khare (S)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Vickie Bowcut (V)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

David M Briere (DM)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Aaron C Burns (AC)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Robin J Gunn (RJ)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Anthony Ivetac (A)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Jon Kuehler (J)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Svitlana Kulyk (S)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Jade Laguer (J)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

J David Lawson (JD)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Krystal Moya (K)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Natalie Nguyen (N)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Lisa Rahbaek (L)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Barbara Saechao (B)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Christopher R Smith (CR)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Niranjan Sudhakar (N)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Nicole C Thomas (NC)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Laura Vegar (L)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Darin Vanderpool (D)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Xiaolun Wang (X)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Larry Yan (L)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Peter Olson (P)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

James G Christensen (JG)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Matthew A Marx (MA)

Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH